The role of endothelin receptor antagonists in kidney disease

The role of endothelin receptor antagonists in kidney disease

Kidney diseases are among the most prevalent conditions worldwide, impacting over 850 million individuals. They are categorized into acute kidney injury and chronic kidney disease. Current preclinical and clinical trials have demonstrated that endothelin (ET) is linked to the onset and progression o...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiaoting Ma, Yuyang Liang, Wenmin Chen, Lingqian Zheng, Haishan Lin, Tianbiao Zhou
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Series:	Renal Failure
Subjects:	Endothelin endothelin receptor antagonist kidney disease chronic kidney disease acute kidney injury
Online Access:	https://www.tandfonline.com/doi/10.1080/0886022X.2025.2465810
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Research trends and performance of endothelin A receptor antagonist in kidney care: a bibliometric analysis
by: Wisit Cheungpasitporn, et al.
Published: (2025-12-01)

Endothelin receptor antagonists (ERAs) can potentially be used as therapeutic drugs to reduce hypertension caused by small molecule tyrosine kinase inhibitors (TKIs)
by: Qingjian He, et al.
Published: (2025-01-01)

EXPERIENCE OF USING THE NONSELECTIVE ENDOTHELIN RECEPTOR ANTAGONIST MACITENTAN IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
by: M. A. Simakova, et al.
Published: (2018-04-01)

Kinetics of endothelin-1 and effect selective ETA antagonism on ETB activation: a mathematical modeling analysis
by: K. Melissa Hallow, et al.
Published: (2024-11-01)

Endothelin receptor antagonists target EDNRB and modulate the progression of idiopathic pulmonary fibrosis via anoikis-related genes
by: Pengfei Ning, et al.
Published: (2025-06-01)

Shear Stress-Dependent Modulation of Endothelin B Receptor: The Role of Endothelial Glycocalyx Heparan Sulfate
by: Camden Holm, et al.
Published: (2025-07-01)

A Pilot Study on Protective Effect of Ambrisentan on Proteinuria in Patients With Alport Syndrome
by: Zhuo-ran Song, et al.
Published: (2024-10-01)

OPPORTUNITIES FOR OPTIMIZATION OF DRUG THERAPY BY ENDOTHELIN RECEPTOR ANTAGONISTS FOR THE PATIENT WITH IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION AND ATRIAL SEPTOSTOMY
by: V. V. Gramovich, et al.
Published: (2018-12-01)

CLINICAL CASE OF COMBINATION THERAPY INCLUDING AMBRIZENTAN IN THE PATIENT WITH SEVERE IDIOPATHIC PULMONARY ARTERIAL HYPERTENSION
by: G. A. Movsisyan, et al.
Published: (2017-06-01)

Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review
by: Kisho Miyasako, et al.
Published: (2024-12-01)

Estimation of Endothelin-1 and Vitamin D Levels in Patients with Some Renal disease
by: Ihsan Maher Abdul Amir, et al.
Published: (2019-12-01)

HJP 272, an endothelin receptor antagonist, and its role in cancer cell migration and invasion
by: Nabeela Baig, et al.
Published: (2025-10-01)

Diagnostic value of ET-1 and UA in early kidney injury of pregnancy-induced hypertension
by: 蔡静, et al.
Published: (2017-01-01)

The Role of Endothelin‐1, Kidney Function and Diabetes in Patients With Coronary Artery Disease Underwent Percutaneous Coronary Intervention
by: Zixiang Ye, et al.
Published: (2025-07-01)

AMBRISENTAN: THE POSSIBILITY OF THE TREATMENT FOR PULMONARY ARTERIAL HYPERTENSION WITH THE SELECTIVE BLOCKADE OF THE ENDOTHELIN SYSTEM
by: T. V. Martynuk, et al.
Published: (2014-03-01)

The extracellular matrix protein type I collagen and fibronectin are regulated by β-arrestin-1/endothelin axis in human ovarian fibroblasts
by: Ilenia Masi, et al.
Published: (2025-02-01)

THE ROLE OF ENDOTHELIN-1 IN VASCULAR HEMOSTASIS OF PERIODONTAL TISSUES
by: N.V. Yarychkivska
Published: (2018-03-01)

Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy
by: Hiddo J.L. Heerspink, et al.
Published: (2025-01-01)

Targeting endothelin receptor signalling overcomes heterogeneity driven therapy failure
by: Michael P Smith, et al.
Published: (2017-06-01)

Modern concept — renal continuum (acute kidney injury, acute kidney disease, chronic kidney disease)
by: A. M. Shutov, et al.
Published: (2021-03-01)

ENDOTHELINES AND CARDIOVASCULAR PATHOLOGY
by: A. M. Alieva, et al.
Published: (2014-11-01)

Rational pharmacotherapy of chronic heart failure with increased endothelin-1 activity: beta-adrenoblocker nebivolol place
by: L. I. Olbinskaya, et al.
Published: (2007-02-01)

Acute Kidney Injury in the Neonatal Period: Retrospective Data and Implications for Clinical Practice
by: Meidad Greenberg, et al.
Published: (2025-07-01)

Evaluation of the serum levels of endothelin-1 and lipid profile in chronic periodontitis patients, before and after periodontal therapy
by: Vanathy Desingu, et al.
Published: (2024-11-01)

The Many Faces of Protease-Activated Receptor 2 in Kidney Injury
by: Yuji Oe, et al.
Published: (2025-02-01)

The New Drugs in the Treatment of Hypertension and Resistant Hypertension: A Review of Therapies
by: Mateusz Szymon Muras, et al.
Published: (2025-04-01)

FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
by: M. S. Shamkhalova, et al.
Published: (2023-12-01)

Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists
by: Biykem Bozkurt, et al.
Published: (2025-07-01)

The pathogenetic mechanisms of acute kidney injury and chronic kidney disease (a literature review)
by: T. M. Boychuk, et al.
Published: (2018-04-01)

Hereditary features of plasma concentrations of endothelin-1 in men with hypertension and chronic heart failure
by: H. O. Palahniuk, et al.
Published: (2016-12-01)

Risk of chronic kidney disease in children who developed acute kidney injury secondary to nephrotoxic medication exposure in infancy
by: Priyanka Ameta, et al.
Published: (2023-12-01)

Endothelial dysfunction in acute renal injury in children with hemolytic-uremic syndrome (literature review)
by: E. V. Gunkova, et al.
Published: (2021-06-01)

Research advances of applications of urinary angiotensinogen for kidney disease
by: Bai Yu-huan, et al.
Published: (2021-01-01)

INHERITANCE OF POLYMORPHIC GENOTYPES OF THE ENDOTHELIN-1 GENE AND INDICATORS OF CARDIAC AND SYSTEMIC HEMODYNAMICS IN MEN WITH ESSENTIAL HYPERTENSION, RESIDENTS OF PODILLYA
by: H.O. Palahniuk, et al.
Published: (2017-03-01)

Elucidating essential kinases of endothelin signalling by logic modelling of phosphoproteomics data
by: Alexander Schäfer, et al.
Published: (2019-08-01)

The deleterious effects of CDK4/6 inhibition on renal recovery post-acute kidney injury
by: Shanshan Zhou, et al.
Published: (2024-11-01)

The Effect of Autologous Dendritic Cell Therapy on Renal Perfusion in Diabetic Kidney Disease: Analysis of Doppler Ultrasound and Angiogenesis Biomarkers
by: Ardianto Pramono, et al.
Published: (2025-04-01)

Biochemical predictors of chronic kidney disease in children recovering from acute kidney injury
by: O. V. Lavrenchuk, et al.
Published: (2021-02-01)

Meta-analysis of piperazine ferulate combined with angiotensin receptor antagonist in the treatment of diabetic kidney disease
by: LIU Tong-tong, et al.
Published: (2020-01-01)

Endothelin Level and Its Correlation with Uric Acid in Type 2 Diabetic Multiuse Patients
by: Zahraa Majid Ismail, et al.
Published: (2020-08-01)